Synonyms: CB-313 | Lysodren®
mitotane is an approved drug (FDA (1970), EMA (2004))
Compound class:
Synthetic organic
Comment: The molecular mechanism underlying mitotane's clinical effects is complex and poorly understood [1].
|
|
No information available. |
Summary of Clinical Use ![]() |
Used to treat inoperable adrenal cortical carcinoma (ACC), where it specifically causes the death of these cells and inhibits their production of steroid hormones. |
Mechanism Of Action and Pharmacodynamic Effects ![]() |
The precise molecular mechanism underlying mitotane's clinical effects has not been fully resolved, but may include: inhibition of steroidognesis as it is believed to inhibit two of the cytochrome P450 enzymes (CYP11A1 and CYP11B1) [2] essential for initiating steroid hormone biosynthesis and the drug may also cause apoptosis via activation of caspases 3 and 7 [1]. |
External links ![]() |
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com European Medicines Agency (EMA) |